PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: C07F 9/14, C07K 1/00, 1/04, C07F 9/12

A1 (11) International Publication Number:
(43) International Publication Date:

WO 98/12201

26 March 1998 (26.03.98)

(21) International Application Number:

PCT/GB97/02592

(22) International Filing Date:

23 September 1997 (23.09.97)

(30) Priority Data:

9619768.6

23 September 1996 (23.09.96) GB

(71) Applicant (for all designated States except US): THE UNIVER-SITY COURT OF THE UNIVERSITY OF ST. ANDREWS [GB/GB]; 66 North Street, St. Andrews, Fife KY16 9AH (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GANI, David [GB/GB], Bois Feuris, Crail Road, St. Andrews, Fife KY16 8AP (GB). HILLIER, Mark [GB/GB]; 133B South Street, St. Andrews KY16 9UN (GB). HORMOZDIARI, Pantea [IR/GB]; 19 All Saints Court, Didcot, Oxon OX11 7NG (GB).

(74) Agent: MURGITROYD & COMPANY; 373 Scotland Street, Glasgow G5 8QA (GB). (81) Designated States: AL., AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CII, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, Cl, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(54) Title: PHOSPHORYLATING REAGENTS

(57) Abstract

There is provided a phosphorylating reagent for phosphrylation of amino acids or compounds formed therefrom. The phosphorylating reagent is of utility in solution or solid-phase chemistry, and particularly for the solid-phase synthesis of phosphorylated peptides and combinational libraries of phosphorylated organic compounds. Also provided for is a method of phosphorylating oxygen, nitrogen and sulphur nucleophides, for example amino acid and peptides.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL.	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	1.ithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	MI.	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	บร	United States of Americ
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Vict Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
СН	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	Pl.	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ.	Kazaksian	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Gernany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
KE	Estonia	LR	Liberia	SG	Singapore		

1

Phosphorylating Reagents

2 3 This invention describes novel phosphorylating reagents and the use thereof for solution or solid-phase 4 5 chemistry and their particular use for the solid-phase 6 synthesis of phosphorylated peptides and combinatorial 7 libraries of phosphorylated organic compounds. 8 9 The reversible phosphorylation of proteins on serine, 10 threonine and tyrosine residues, as catalysed by 11 protein kinases and phosphatases, is the principal 12 mechanism by which eukaryotic cells (the cells of 13 multicellular organisms) respond to external stimuli1.2. 14 Three groups of enzymes referred to collectively as the 15 protein phosphatases (these enzymes hydrolyse the 16 phosphoryl group of a phosphoprotein) are responsible for the dephosphorylation of the phosphoproteins. 17 18 group known as the serine-threonine protein 19 phosphatases are collectively responsible for the dephosphorylation of certain phosphorylated serine or 20 threonine residues within phosphoproteins (see Fig. 1A) 21 and several different types exist (e.g. PP1, PP2A, PP2B 22 23 and PP2C) most of which appear to be associated with 24 regulatory proteins. A second group are referred to as 25 the protein tyrosine phosphatases and these enzymes

hydrolytically remove the phosphoryl group from certain phosphotyrosine residues within phosphoproteins, Fig. B. The third group of enzymes is responsible for removing the phosphoryl group from phosphohistidine residues within phosphoproteins, Fig. 1C.

6

WO 98/12201

Structure-activity studies for the phosphorylated 7 peptide substrates of protein phosphatases have been 8 limited by the availability of structurally diverse 9 substrates because, to date, almost all of these have 10 been prepared by enzymic phosphorylation using 11 adenosine triphosphate (ATP) and appropriate protein 12 kinase enzymes which are specific for certain 13 sequences3. The specific nature of these enzymes 14 restricts the scope of these studies in addition to the 15 extra complications of separating the products of the 16 reaction e.g. separating the phosphorylated peptide 17 from adenosine monophosphate (AMP). Moreover, non-18 enzymic syntheses of phosphopeptides, in particular 19 phosphothreonine peptides is severely hampered by β -20 elimination of phosphoric acid diester which occurs in 21 synthetic intermediates to give the corresponding 22 dehydroamino acid moieties4-6. Phosphothreonine peptide 23 syntheses typically employ large excesses of highly 24 electrophilic phosphorus (III) reagents to introduce 25 phosphorus into the preformed peptide and then an 26 oxidant (e.g.tertiary-butyl hydroperoxide) is required 27 to convert the phosphite triester to the phosphate 28 triester prior to deprotection of the ester groups 4.5. 29 While the peptide exists as its phosphate triester, it 30 is particularly vulnerable to β -elimination, which is 31 32 undesirable.

33

34 The existing methods for avoiding β -elimination in the 35 synthesis of phosphoserine and phosphothreonine 36 peptides involve introducing each of the phosphorylated

amino acid residues as their protected phosphate diester monoanions⁶. These are however tedious to prepare.

It is an object of the present invention to provide a phosphorylating agent that would be electrophilic enough to react directly and rapidly with primary and secondary alcohol groups within resin-bound peptides. Such agents would obviate the need for an oxidant, and could possess labile phosphate ester protecting groups that would be compatible with solid-phase peptide synthesis.

This invention provides an electrophilic phosphorylating reagent for amino acids and/or peptide sequences thereof comprising a compound as represented by formula (I):

$$F \xrightarrow{A} X'''$$

$$X'''$$

$$X'''$$

$$X'''$$

$$X''''$$

wherein: A is a substituted aromatic group which is represented by formula (II) e.g. a fluorophenyl or A is an acid cleavable functionality such as a benzyl or substituted benzyl group represented by formula (III); B is a substituted aromatic group represented by formula (II) e.g. a fluorophenyl group, but not a

WO 98/12201

benzyl or a substituted benzyl group; 1 each X, X', X'', X''' and X'''' are individually H or F 2 atoms or any suitable moiety; 3 Y is any halogen or leaving group. 4 5 The leaving group Y is the group which does not contain 6 the phosphorous atom following cleavage of compound I; 7 8 for example Y can be Cl, Br, I, -NRR'R''(as a quaternary ammonium salt), -OR, -SR (wherein each group R, R' or R" 9 is any group which does not affect the lability of the 10 11 leaving group Y, especially under acidic and/or basic conditions, for example R, R' or R" can individually be 12 13 -H, -CH₃, -C₂H₅, -C₆H₅, -C(0)-C₁₋₁₂ or -CH=C(OH)-C₁₋₁₂). 14 The reference to "any suitable moiety" with regard to 15 groups X, X', X'', X''' and X'''' refers to any atom or 16 group thereof which does not affect the lability of the 17 compounds represented by formulae II or III. 18 19 In one embodiment, the reagent is bis(tetrafluorophenyl) 20 chlorophosphate; and in this embodiment the preferred 21 reagent is bis (2, 3, 5, 6-tetrafluorophenyl) 22 23 chlorophosphate. 24 In a further embodiment, the reagent is a benzyl, 25 fluorophenyl halophosphate; and in this embodiment the 26 preferred reagent is a benzyl, polyfluorophenyl 27 chlorophosphate. 28 29 It can be seen that reagents represented by the formula 30 (I) have a fluorine in at least one ortho position on at 31 least one of the aromatic rings wherein the remaining 32 33 positions X, X', X'' and X''' on (II) and X, 34 X', X'', X''' and X'''' on (III) can each be -H or -F 35 atoms or any suitable moiety in any permutation. 36

1 2 Additionally, the -H atom or -F atom or suitable moiety may be in the presence or absence of one or more 3 4 similar or dissimilar other ring substituents. A further embodiment has a halogen or other leaving 6 7 group attached to the phosphorus atom of reagent (I) at Y, where the leaving group can be one of -OR, -NRR', 8 -NRR'R'' or -SR, wherein R, R' and R'' can be any 9 10 suitable moiety. 11 The invention further provides a method for the 12 13 phosphorylation of oxygen, nitrogen or sulphur 14 nucleophiles of amino acids and/or peptides wherein the nucleophile is treated with an excess of a reagent of 15 general formula (I) followed by hydrolysis of the 16 17 product. 18 19 Preferably the hydrolysis reagent is trifluoroacetic 20 acid. 21 22 The oxygen nucleophile may be part of a primary or 23 secondary alcohol, phenol, carboxylate or enolate 24 group. 25 26 The amino acids may be present as single species or in 27 combination within or outwith the same molecule, as in 28 peptide sequences. 29 30 Suitably, the amino acid(s) may be tyrosine, serine and 31 threonine. 32 33 In one particular embodiment of the invention, the 34 amino acid is present as a resin bound moiety. 35 36 In further embodiments of the invention, the

phosphorylation method may be utilised in solid, liquid 1 2 or gel phase. 3 The method is of considerable potential in the solid-4 phase synthesis of a whole range of organic phosphates 5 from primary and secondary alcohols and phenols and is 6 completely compatible with combinatorial and 7 permutational organic synthesis. 8 9 In the area of peptide chemistry the method offers very 10 significant advantages over the previously used two 11 step phosphitylation-oxidation strategies, 12 furthermore, the use of bis-(pentafluorophenyl) 13 chlorophosphate (11) is of particular utility in the 14 preparation of peptides containing two or more 15 phosphorylated residues via a "global phosphorylation" 16 strategy which involves introducing all of the 17 phosphoryl groups in one step after the synthesis of 18 the required peptide. The same is true for the 19 introduction of more than one phosphoryl group into 20 other organic molecules which contain more that one 21 alcohol and/or phenol group. 22 23 The examples illustrate that primary alcohols, 24 secondary alcohols and phenols whether present as 25 single species, or in combination within or outwith the 26 same molecule, are efficiently phosphorylated by the 27 polyfluoroaromatic chlorophosphate reagents. Other 28 oxygen nucleophiles, for example, carboxylate and 29 enolate, and other nucleophiles, for example, those 30 derived from nitrogen and sulphur are also expected to 31 react with similar efficiency with the reagent. 32 33 The examples herein relate to the phosphorylation 34 reaction by bis-(pentafluorophenyl chlorophosphate (11) 35 and other polyfluoroaromatic halophosphates shown by 36

1	general	formula I, where any, some or all X groups is H
2	and/or F	or other suitable moiety in any permutation
3	whether	in the presence or absence of one or more
4	similar o	or dissimilar other ring substituents; (Y is a
5	halogen d	or other leaving group) which should effect a
6	similar :	facile phosphorylation. Furthermore,
7	triesters	s, derived from oxygen nucleophiles, or any
8	other pho	osphorylated derivative containing the
9	polyfluo	roaromatic phosphate diester protection;
10	wherein Y	<pre>/ = -OR,-NRR',-NRR'R'', -SR, (where each group</pre>
11	R, R' or	R'' can be any suitable moiety as defined
12	above) sh	hould be more labile to deprotection under
13	acidic co	onditions (and/or under basic conditions) than
14	the corre	esponding bis-phenyl phosphate diester
15	protectio	on.
16		
17	This meth	od provides higher yields of phosphorylated
18	product c	f high quality with less or no wasteful side
19	reactions	
20		
21	This inve	ntion is further described in a non-limiting
22	manner by	reference to the following examples and
23	accompany	ing figures wherein:
24		
25	Fig. la	Illustrates the enzymatic dephosphorylation
26		of a phosphorylated threonine (or serine)
27		residue.
28		
29	Fig. 1b	Illustrates the enzymatic dephosphorylation
30		of a phosphorylated tyrosine residue.
31		
32	Fig. 1c	Illustrates the enzymatic dephosphorylation
33		of a phosphorylated histidine residue.
34		
35	Fig. 2:	Illustrates reaction schemes 1A & 1B.
36		Reagents and Conditions: i) 20%

```
piperidine/DMF; ii) 5% (CH<sub>3</sub>CO)<sub>2</sub>O/DMF; iii)
 1
                  DMAP, TEA, PO(OPh)2Cl, DCM, 20°C; iv) 82.5%
 2
                  TFA: 5% phenol: 5% H<sub>2</sub>O: 5% thioanisole; 2.5%
 3
                  EDTA (reagent K), 80%; v) LiOH (ag),
 4
                  EtOH/CH3CN; vi) DMAP, TEA, PO(OPhF5)2Cl, DCM,
 5
                  20°C; vii) Dowex Cl, 60%.
 6
 7
                 Shows the structure of bis(pentafluorophenyl)
      Fig. 3a:
 8
                  chlorophosphate (11).
 9
10
                  Shows the structure of the
      Fig. 3b:
11
                  bis(pentafluorophenyl) phosphate derivative
12
                  of cyclohexanol (12).
13
14
                  Shows the structure of pentafluorobenzyl-
15
      Fig. 4:
                  pentafluorophenyl chlorophosphate (13).
16
17
                  Illustrates reaction scheme 2.
                                                      Reagents and
      Fig. 5:
18
                  Conditions: i) 1.01 eq N-Chlorosuccinimide,
19
                  toluene, 2hr, rt: ii) NaH, C<sub>6</sub>F<sub>5</sub>OH, THF, 1hr,
20
                  rt; iii) a) NaI, acetone, \triangle, 15 mins. b)
21
                  HCl<sub>(aq)</sub>; iv) PCl<sub>5</sub>, DCM.
22
23
                  Shows the structure of the benzyl
24
       Fig. 6a:
                  pentafluorophenyl derivative of cyclohexanol
25
                  (18).
26
27
                  Shows the structure of the benzyl
       Fig. 6b:
28
                  pentafluorophenyl derivative of N-\alpha-{}^{t}Boc-
29
                  tyrosine methyl ester (19).
30
31
                  Shows the structure of the phosphopeptide
32
       Fig. 6c:
                  Asp-Ala-Asp-Glu-Tyr(OPO<sub>3</sub>H<sub>2</sub>)-Leu (23).
33
34
                  Illustrates reaction scheme 3.
                                                       Reagents and
       Fig. 7:
35
                  Conditions: i) 20% piperidine/DMF; ii) DMAP,
36
```

```
TEA, PO(OCH<sub>2</sub>Ph)(OPhF<sub>5</sub>), DCM, 20°C; iii) NaOH
   1
   2
                   (aq), DMSO; iv) 90% TFA, 5% H<sub>2</sub>O, 5% Et<sub>3</sub>SiH.
   3
   4
        Example 1
   5
        Diphenyl chlorophosphate had been successfully employed
   6
        to phosphorylate the secondary alcohol groups of myo-
   7
        inositol and its analogues'. Using an N-acetyl (Ac)
   8
        capped analogue of a known consensus sequence for a
   9
        PP2A substrate as the target, AcNH-Arg-Arg-Ala-
 10
 11
        Thr(PO_3H_2)-Val-Ala-OH (1), a series of solid-phases
        phosphorylation reactions were examined. Accordingly,
 12
 13
       using Wang resin, standard Fmoc chemistry with PyBOP
       activation, and arginine residue precursors containing
 14
 15
       2,2,5,7,8-pentamethylchroman-6-sulphonyl (Pmc)
       protected guanidino groups, the peptide Fmoc-NH-Arg-
 16
 17
       Arg-Ala-Thr-Val-Ala-O-Wang (2) was prepared.
       terminal Fmoc group was removed with 20% piperidine in
 18
 19
       DMF and the free amino group was capped with 5% acetic
 20
       anhydride in DMF to give compound (3). Treatment of
 21
       the resin-bound peptide (3) with diphenyl
       chlorophosphate gave some of the required diphenyl
 22
       threonine phosphate triester (4), and under optimised
23
       conditions (repeated treatments with 20 equivalents of
24
       diphenyl chlorophosphate in the presence of DMAP and
25
      TEA for 6-8 hours at ambient temperature) essentially
26
      quantitative conversion to the triester (4) could be
27
      achieved, as determined by NMR-spectroscopic analysis
28
      of the products after cleavage from the resin Fig. 2,
29
30
      Scheme 1A.
31
      ^{1}\mathrm{H-}, ^{13}\mathrm{C-} and ^{31}\mathrm{P-NMR} spectra showed the expected
32
33
      signals, chemical shift changes and P-C and P-H
      couplings for the required triester (5). All attempts
34
      to hydrolyse the pure triester (5) under mild basic
35
      conditions resulted in the formation of significant
36
```

10

quantities of the eta-elimination product, 1 dehydrobutyrine peptide (6), as judged by H- and Hp-2 NMR spectroscopy. 3 4 Example 2 5 6 In order to increase the electrophilicity at phosphorus 7 in the phosphorylating species (to decrease reaction 8 times) and also in the required peptide phosphate 9 triester (to facilitate deprotection), the preparation 10 and use of bis-(pentafluorophenyl) chlorophosphate (11) 11 was investigated. The reagent was prepared by treating 12 phosphorus oxychloride (7) with 1.8 equivalents of 13 pentafluorophenol (8) at 140°C for 16-24 hours and was 14 purified by removing the unreacted starting materials 15 by distillation. The resulting reagent (11) was 85-90% 16 pure as judged by 19F- and 31P-NMR spectroscopy and could 17 be further purified by fractional distillation. 18 19 $POCl_3 + 2 C_6HF_5O \longrightarrow (C_6F_5O)PClO + 2 HCl$ 20 21 22 Example 3 23 In model reactions using cyclohexanol, the bis-24 (pentafluorophenyl) chlorophosphate (11) reacted at 25 least 30-fold more rapidly than diphenyl 26 chlorophosphate to give the required triester (12) 27 which was fully characterised. Note that the bis-28 (2,3,5,6-tetrafluorophenyl) chlorophosphate analogue of 29 reagent (11), which was more useful for mechanistic 30 studies and for product characterisation (due to the 31 presence of an integratable proton resonance in ¹H-HMR 32

spectra), behaved similarly in effecting rapid

35

33

34

phosphorylation.

1	Example 4
2	
3	Treatment of the Pmc protected resin-bound peptide, Ac
4	NH-Arg-Arg-Ala-Thr-Ala-Val-Ala-O-Wang(3), with 10
5	equivalents of bis-(pentafluorophenyl) chlorophosphate
6	under optimised conditions gave the resin-bound
7	phosphate triester (9) in excellent yield, Scheme 2B.
8	Immediate deprotection of the two Pmc groups, the two
9	pentafluorophenyl groups, and simultaneous cleavage
10	from the resin occurred upon treatment with aqueous
11	trifluoroacetic acid solutions to give the almost pure
12	N-capped phosphorylated threonine peptide (10) in
13	essentially quantitative conversion. There was no
14	evidence whatsoever for eta -elimination products and
15	purification on Dowex 1 chloride (Trade Mark) gave the
16	pure phosphopeptide (10) in 60% overall yield (over 14
17	solid-phase steps). This material was fully
18	characterised and served as a substrate for protein
19	phosphatase λ as judged by directly monitoring the
20	course of phosphopeptide hydrolysis by H-NMR
21	spectroscopy.
22	
23	Example 5
24	
25	Other peptides containing serine residues or tyrosine
26	residues were also successfully phosphorylated with
27	bis-(pentafluorophenyl) chlorophosphate (11) using
28	similar protocols.
29	
30	Example 6
31	
32	Merrifield resin bound inositol analogues, connected by
33	ether linkages which are stable to trifluoroacetic
34	acid, were successfully phosphorylated on secondary
35	alcohol moieties by bis-(pentafluorophenyl)
36	chlorophosphate (11) using similar protocols.

12

Treatment with aqueous trifluoroacetic acid resulted in 1 the deprotection of the pentafluorophenyl groups to 2 give resin bound inositol monophosphate analogues. 3 $(\delta p (121.41 \text{ MHz}, C_6^2 H_6): -10.443).$ 4 5 6 Example 7 7 In both solution and solid phase phosphorylations of 8 phenols it was noted that, whilst the actual 9 phosphorylation reaction with bis-(pentafluorophenyl) 10 chlorophosphate (11) was facile, complete removal of 11 the pentafluorophenyl groups was difficult. 12 case, the first pentafluorophenyl group could be 13 removed easily in the presence of trifluoroacetic acid 14 solution, but the second pentafluorophenyl group could 15 Therefore, since it appeared that the acidity of 16 the partially deprotected phosphoric acid derivative 17 was too high for protonation by the trifluoroacetic 18 acid solution, modified reagents were designed, [for 19 example preferably formula I, where II is a substituted 20 phenyl group (where X, X', X'', X''' are H or F atoms 21 or any suitable moiety), III is a benzyl or substituted 22 benzyl group (where X, X', X'', X''', X'''' are H or F 23 atoms or any suitable moiety) but not a phenyl or 24 substituted phenyl group, and Y is any halogen. It was 25 expected that the phenyl or substituted phenyl group 26 (derived from the reagent) of the intermediate triester 27 (phosphorylated alcohol or phenol) would be removed in 28 a facile manner by base catalysed hydrolysis, and that 29 the benzyl or substituted benzyl group could be removed 30 in a facile manner by acid catalysed hydrolysis, 31 preferably in the presence of trifluoroacetic acid, 32 which would be compatible with other solid state 33 synthesis protocols. 34

35

36 To prepare such substituted phenyl substituted benzyl

13

halophosphates, a model synthetic protocol was 1 developed using benzyl pentafluorophenyl chlorophospate 2 as the target (Scheme 2). 3 4 Treatment of dibenzyl phosphite (14) with N-5 chlorosuccinimide in toluene8, followed by reaction with 6 sodium pentafluorophenolate (formed by the reaction 7 between sodium hydride and pentafluorophenol in THF) 8 resulted in the formation of dibenzyl pentafluorophenyl 9 phosphate triester (15). ¹H, ¹³C, ¹⁹F and ³¹P-NMR spectra 10 showed the expected chemical shift changes and P-C and 11 P-H coupling constants consistent with those expected 12 for the required triester. $\delta_{H}(300 \text{ MHz}, C^{2}HCl_{3}):5.21 \text{ (d,}$ 13 $J_{PH}8.7$, CH_2OP), $\delta_c(75.4 \text{ MHz}, C^2HCl_3):70.88$ (d, CH_2OP , J_{PC} 14 6.5), $\delta p(121.41 \text{ MHz}, C^2HCl_1): -5.44$, and the correct 15 mass ion (m/z(CI+ mode) 444, M' molecular ion).16 17 Reaction of the triester (15) with 1 equivalent of 18 anhydrous sodium iodide in refluxing acetone for 15 19 minutes gave a white solid, which upon cooling was 20 isolated by filtration, then dissolved in water and 21 treated with aqueous hydrochloric acid. 9 The resulting 22 precipitate of benzyl pentafluorophenyl phosphoric acid 23 diester (16) was isolated in essentially quantitative 24 yield from the dibenzyl pentafluorophenyl phosphate 25 triester (15). ¹H, ¹³C, ¹⁹F and ³¹P-NMR spectra showed 26 the expected chemical shift changes and P-C and P-H 27 coupling constants for the required diester. δ_{H} , (300) 28 29 MHz, C^2HCl_3):5.20 (2H, d, J_{PH} 8.4, CH_2OP), δ_C (75.4 MHz, $C^{2}HCl_{3}$):70.92 (d, $CH_{2}OP$, J_{PC} 5.4), δ_{P} (121.41 MHz, $C^{2}HCl_{3}$): 30 Mass spectrometry confirmed the desired product 31 had been obtained (m/z) (EI+ mode): 354 (M molecular 32 33 ion)). Reaction of benzyl pentafluorophenyl phosphoric acid diester (16) with an excess of PCl, in 34 dichloromethane followed by removal of the solvent at 35 36 reduced pressure (20mm/Hg) and separation of the by-

PCT/GB97/02592 WO 98/12201

14

products by distillation at 0.1 mm Hg/30-40°C afforded 1 the reagent (17) in better than 75% purity as judged by 2 ¹H and ³¹P-: 1R. $\delta_{\rm H}(300~{\rm MHz},~{\rm C^2HCl_3}):5.38~(2H,~{\rm d},~J_{\rm PH}~9.9,$ 3 CH_2OP), $\delta_C(75.4 \text{ MHz}, C^2HCl_3):72.91 (d, <math>CH_2OP$, J_{PC} 7.54), 4 $\delta_p(121.41 \text{ MHz}, C^2HCl_3)$: main peak at -2.39. Mass 5 spectrometric analysis also gave the expected data (m/z6 (EI+): 372, 374 (Cl isotopes, M molecular ion). 7 reagent was found to be unstable at high temperatures 8 (50°C) and decomposed if heated for prolonged periods 9 above that temperature. The major contaminant 10 displayed 2 signals at -18.6 and -19.5 ppm in the 31p 11 NMR spectrum of the product and corresponding signals 12 in the ^{1}H , ^{13}C and ^{19}F NMR spectra, consistent with the 13 expected properties of the bis-(benzyl)-bis-14 (pentafluorophenyl) pyrophosphate. The mass spectrum 15 of the contaminant showed a molecular fragment (m/z16 (CI+) 507, $[M-OPhF_5]^+$) consistent with the structure of 17 the pyrophosphate. Since this material would give 18 identical phosphorylated products to the 19 chlorophosphate, the crude reagent was used routinely 20 for solid phase phosphorylations. 21 22 Other benzyl phenyl chlorophosphates were prepared 23 using analogous methods. 24 25 26 Example 8 27 In model phosphorylation reactions in solution using 28 cyclohexanol, the benzyl pentafluorophenyl 29 chlorophosphate (17) reacted with cyclohexanol in the 30 presence of triethylamine in dichloromethane to give 31

the required triester (18). This was characterised by 1H, 13C, 19F and 31P-NMR spectroscopy and gave the expected data.

34 35

32

33

1	Example 9
2	
3	In model phosphorylation reactions in solution using
4	N-tBoc-(2S)-tyrosine methyl ester, the benzyl
5	pentafluorophenyl chlorophosphate (17) reacted with the
6	phenolic hydroxyl group in the presence of
7	triethylamine in dichloromethane to give the required
8	triester(19). This was characterised by ¹ H, ¹³ C, ¹⁹ F and
9	³¹ P-NMR spectroscopy and mass spectrometry and gave the
10	expected data.
11	
12	Example 10
13	
14	In model solid state phosphorylation reactions,
15	treatment of the resin-bound peptide Fmoc-Val-Tyr-Leu-
16	O-Wang (20) with 10 equivalents of freshly prepared
17	benzyl pentafluorophenyl chlorophosphate (17) under
18	optimised conditions gave the resin bound phosphate
19	triester (21) in excellent yield, Scheme 3. Treatment
20	with 20% piperidine in DMF removed the N-terminal Fmoc
21	group. Subsequent treatment of the product with an
22	excess of 1 mol.dm ⁻³ aqueous NaOH in DMSO followed by
23	washing and treatment with ageuous trifluoroacetic acid
24	resulted in deprotection of the pentafluorophenyl and
25	benzyl groups and cleavage of the resin C-terminal
26	ester linkage to give the phosphopeptide Val-
27	Tyr(OPO ₃ H ₂)-Leu (23), δ_p (121.41 MHz, 2H_2O):-3.42.
28	
29	Example 11
30	
31	Treatment of the tris-tert-butyl ester protected resin
32	bound peptide Fmoc-NH-Asp(O'Bu)-Ala-Asp(O'Bu)-Glu(O'Bu)-
33	Tyr-Leu-O-Wang in a similar manner to that described in
34	Example 10 above afforded the almost pure hexapeptide
35	Asp-Ala-Asp-Glu-Tyr(OPO ₃ H ₂)-Leu (24) which showed the

expected NMR spectroscopic data. This product

16

corresponds to the structure of the autophosphorylation 1 site of the epidermal growth factor receptor (EGFR) 10 in 2 its phosphorylated form. 3 4 Example 12 5 6 Treatment of the resin bound and protected peptide Ac-7 NH-Arg(Pmc)-Arg(Pmc)-Ala-Thr-Val-Ala-O-Wang (3) with 10 8 equivalents of benzyl pentafluorophenyl chlorophosphate 9 (17) under optimised conditions gave the benzyl 10 pentafluorophenyl peptide phosphate triester. 11 Treatment of the resulting triester overnight with an 12 excess of 1 mol.dm⁻³ aqueous NaOH in DMSO followed by 13 washing and subsequent treatment with aqueous 14 trifluoroacetic acid resulted in deprotection of the 15 two 2,2,5,7,8-pentamethylchroman-6-sulphonyl (Pmc) 16 groups, the pentafluorophenyl and benzyl groups and 17 cleavage of the C-terminal resin ester moiety to give 18 the almost pure N-capped phosphohexapeptide (10). 19 Spectroscopic data showed this material to be identical 20 to that prepared in Example 4 above. 21

22

The serine analogue of (10) was prepared using a similar protocol.

1 References 2 3 1. T Hunter, Cell, (1995), 80, 225. a) P Cohen, Annu. Rev. Biochem., (1989), <u>58</u>, 453: 5 2. b) R T W Cohen, N D Brewis, V Hughes and D J Mann, 6 7 FEBS Lett., (1990), 268 255. 8 9 a) A Donella-Deana, C H MacGowan, P Cohen, F 3. 10 Marchiori, H E Meyer and L A Pinna, Biochem. 11 Biophys. Acta, (1990), 1051, 199: b) L A Pinna, P 12 Agostinis, A Donella-Deana and F Marchiori, 13 Adv.Prot. Phosphatases, (1989), 5, 51 14 15 4. A Paquet and M Johns, Int. J. Peptide Protein 16 Res., (1990), <u>36</u>, 97. 17 18 a) E A Kitas, J W Perich, G W Tregear and R B 5. Johns, J Org. Chem., (1990), 55, 4181; b) E A 19 20 Kitas, J W Perich, R B Johns and G W Treagear, 21 Tet. Lett., (1988), 29, 3591. 22 23 6. T Vorherr and W Bannwarth, Bioorg. Med. Chem. 24 Lett., (1995), <u>5</u>, 2661. 25 26 7. J Schulz, J Wilkie, P Lightfoot, T Rutherford and D Gani, J. Chem. Soc. Chem. Commun., (1995), 2353. 8. R.H.Hall and H.G.Khorana, J.Am. Chem. Soc, (1954), <u>76</u>, 5056. L.Zervas and I.Dilaris, J.Am. Chem. Soc, (1955), 9. <u>77</u>, 5354-6. Z-Y Zhang et al, Biochemistry, (1994), 33, 2285-10.

BNSDOCID: <WO_____ 9812201A1_I >

27

28 29

30

31 32

33

34 35

36

90.

Claims

1 2 3

4

5

An electrophilic phosphorylating reagent for amino 1. acids and/or peptide sequences thereof comprising of a compound represented by formula (I) wherein:

6 7

8 9

10

11

12 13

14

15

16 17

18

19

24 25

26 27

28

29

30

31

32

36

33 34 3. 35

ĊH2 (1) (111) (II)

A is a substituted aromatic group which is represented by formula (II) or A is an acid cleavable functionality such as a benzyl or substituted benzyl group represented by formula (III);

B is a substituted aromatic group represented by formula (II); X, X', X'', X''' and X'''' are each H or F atoms or any suitable moiety; Y is a halogen or leaving group.

A phosphorylating reagent as claimed in Claim 1, 2. wherein at least one of the compounds represented by formulae (II) and (III) is fully substituted by fluorine.

A phosphorylating reagent as claimed in either of Claims 1 and 2 wherein group Y is a chlorine atom.

1	4.	A phosphorylating reagent as claimed in any one of
2		Claims 1 to 3 which is bis(pentafluorophenyl)
3		chlorophosphate .
4		
5	5.	A phosphorylating reagent as claimed in Claim 3
6		which is bis (2, 3, 5, 6 - tetrafluorophenyl)
7		chlorophosphate.
8		
9	6.	A phosphorylating reagent as in any one of Claims
10		1 to 3 where the reagent is a benzyl, fluorophenyl
11		halophosphate.
12		
13	7.	A phosphorylating reagent as in claim 6 where the
14		reagent is a benzyl, polyfluorophenyl
15		chlorophosphate.
16		
17	8.	A method for the phosphorylation of oxygen,
18		nitrogen or sulphur nucleophiles of amino acids
19		and/or compounds comprising an amino acid-like
20		moiety wherein the nucleophile is treated with an
21		excess of a reagent of general formula (I) as
22		defined in Claim 1 followed by the hydrolysis of
23		the product.
24		
25	9.	A method as in claim 8 where the oxygen
26		nucleophile may be part of a primary or secondary
27		alcohol, phenol, carboxylate or enolate group.
28		· · · · · · · · · · · · · · · · · · ·
29	10.	A method as in either one of claims 8 and 9 where
30		the amino acids may be present as single species
31		or in combination within or outwith the same
32		molecule, as in peptide sequences.
33		
34	11.	A method as in claim 10 where the amino acid(s)
35		may be tyrosine, serine and threonine.

BNSDOCID: <WO__ ___ 9812201A1 I >

20

1	12.	A method as in any one of claims 8 to 11 where the
2		amino acid and/or peptide is present as a resin
3		bound moiety.

- 5 13. A method as in any one of claims 8 to 12 where the 6 phosphorylation method may be utilised in solid, 7 liquid or gel phase.
 - 14. A method as in any one of claims 8 to 13 where the hydrolysis reagent is trifluoroacetic acid.

FIGURE 1

FIGURE 2

FIGURE 3A

FIGURE 3B

3/7

FIGURE 4

4/7

SUBSTITUTE SHEET (RULE 26)

FIGURE 5

FIGURE 6A

FIGURE 6B

FIGURE 6C

6/7



Fmoc-Val-Tyr-Leu Wang

20

OH

FIGURE 7

7/7

INTERNATIONAL SEARCH REPORT

Inte mai Application No

A CLASS	SIEICATION OF SUB-			PCI/GB 9	//02592
IPC 6	SIFICATION OF SUBJECT MATTER C07F9/14 C07K1/00 C0	07K1/04	C07F9/12		
According	to International Patent Classification(IPC) or to both nation	nal classification a	and IPC		•
B. FIELDS	SEARCHED				
Minimum d IPC 6	tocumentation searched (classification system followed by ${\sf C07F} - {\sf C07K}$	classification sym	nbols)		
Documenta	ation searched other than minimum documentation to the ex	tent that such do	cuments are include	d in the fields so	earched
Electronic d	data base consulted during the international search (name	of data base and	. where practical, se	arch terms used)
C. DOCUME	ENTS CONSIDERED TO BE RELEVANT				
Category *	Citation of document, with indication, where appropriate,	of the relevant pr	assages		Relevant to claim No.
x	US 3 341 630 A (ROBERT H. BO September 1967 see the whole document	SCHAN) 12	2		1-4
(US 3 341 631 A (CHRISTIAN A. SEIL) 12 September 1967 see the whole document			1,2	
(US 3 408 427 A (ROBERT H. BOSCHAN) 29 October 1968 see the whole document			1,3	
	US 5 245 069 A (JAMES W. MCM September 1993 see the whole document	ANUS) 14			1-14
		-/			
X Further	r documents are listed in the continuation of box C.	<u>[x]</u>	Patent family memb	ers are listed in	Annex
pecial cated	gories of cited documents:				
earlier doc	defining the general state of the art which is not set to be of particular relevance sument but published on or after the international	cite	document published riority date and not i d to understand the intion	n conflict with the	e application but ry underlying the
citation or	which may throw doubts on priority claim(s) or sited to establish the publication date of another rother special reason (as specified)	'Y" docu can	ment of particular re not be considered to	ovel or cannot be when the docu levance; the clar involve an involve	e considered to ment is taken alone med invention
document	referring to an oral disclosure, use, exhibition or ans published prior to the international filing date but the priority date claimed	men in th	ument is combined wits, such combination e art. Thent member of the	uru oue ot wore	other such docu- to a person skilled
e of the actu	ual completion of theinternational search		of mailing of the inte		
	November 1997		04/12/1997		
	ing address of the ISA European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tal. (-31-70) 200 - 200 Tu. 24 554	Autho	nzed officer		
	Tel. (+31-70) 340-2040, Tx. 31 651 epo rti, Fax: (+31-70) 340-3016		Beslier, L		

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Inte mai Application No PCT/GB 97/02592

	etion) DOCUMENTS CONSIDERED TO BE RELEVANT	Relevant to dam No.
ategory *	Citation of document, with indication, where appropriate, of the relevant passages	
	SCHULZ J ET AL: "Synthesis and properties of mechanism-based inhibitors and probes for inositol monophosphatase derived from 6-0-(2'-hydroxyethyl)-(1R,2R,4R,6R)-cycloh exane-1,2,4,6-tetraol" J. CHEM. SOC., CHEM. COMMUN. (JCCCAT,00224936);95; (22); PP.2353-6, THE UNIVERSITY, ST. ANDREWS;SCHOOL CHEMISTRY; FIFE; KY16 9ST; UK (GB), XP002047053 cited in the application see the whole document	1-14
,	JAN HES: "Di(2-tert-butylphenyl) Phosphorochloridate. A new selective Phosphorylating agent." JOURNAL OF ORGANIC CHEMISTRY., vol. 39, no. 25, 1974, EASTON US, pages 3767-3769, XP002047054 see the whole document	1-14
Ρ,Χ	HORMOZDIARI P ET AL: "Highly efficient solid-phase phosphopeptide synthesis using bis(polyfluorophenyl) chlorophosphates: preparation of serine—threonine protein phosphatase substrates" TETRAHEDRON LETT. (TELEAY,00404039);96; VOL.37 (45); PP.8227-8230, THE UNIVERSITY;SCH. CHEM.; ST. ANDREWS, FIFE; KY16 9ST; UK (GB), XP002047055 see the whole document	1-14

INTERNATIONAL SEARCH REPORT

adormation on patent family members

Inter nal Application No PCT/GB 97/02592

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 3341630 A	12-09-67	NONE	
US 3341631 A	12-09-67	NONE	
US 3408427 A	29-10-68	NONE	
US 5245069 A	14-09-93	NONE	

Form PCT/ISA/210 (patent family annex) (July 1992)